Get started
Author

Christian Borel

Observed names: BOREL, Christian, Borel C., Borel, Christian, C Borel, C H BOREL, C H. Borel, C. Borel, C.H. Borel, Christian BOREL
Observed institutions: Inserm, Université de Bretagne Occidentale, Merck KGaA, Darmstadt (Germany), Aix-Marseille Université, Hospital de Sant Pau, Institut Jules Bordet, Institut Gustave Roussy, Centre Hospitalier Universitaire de Besançon, Kreisklinik Trostberg, Institut de Cancérologie Strasbourg, Sorbonne Paris Cité, Centre Hospitalier Universitaire de Montpellier, Centre Georges François Leclerc, Hôpital de la Conception, Assistance Publique – Hôpitaux de Paris, Institut de Cancérologie de Lorraine, Centre Hospitalier de Bretagne Sud, Marqués de Valdecilla University Hospital, Hospital Universitario 12 De Octubre, Hôpital Européen Georges-Pompidou, Centre Léon Bérard, Institut Català d'Oncologia, Roche (France), Centre Hospitalier de Mulhouse, Fédération Francophone de Cancérologie Digestive, Pitié-Salpêtrière Hospital, Centre François Baclesse, Hôpital Saint-Louis, Hôpital de la Timone, Université de Bretagne Occidentale, Institut Strauss, Université de Strasbourg, Institut Curie
ORCID: 0000-0002-7710-2086
Observed ORCID: 0000-0002-7710-2086
OpenAlex ID: A5015396175
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
1998 · Y Bécouarn, M Ychou, et al. · Journal of Clinical Oncology · 300
Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
2003 · T. Petit, M. Wilt, et al. · European Journal of Cancer · 264
Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer
1990 · Claude Jacquillat, Marise Weil, et al. · Cancer · 262
PDF
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
2021 · Joël Guigay, Anne Aupérin, et al. · The Lancet Oncology · 249
PDF
Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
2006 · Jean Bourhis, Fernando Rivera, et al. · Journal of Clinical Oncology · 175
Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial
2018 · Lionnel Geoffrois, Laurent Martin, et al. · Journal of Clinical Oncology · 151
Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.
1993 · D Khayat, C Borel, et al. · Journal of Clinical Oncology · 149
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab
2019 · Anthony Dohan, Benoit Gallix, et al. · Gut · 139
LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
2021 · J. Bourhis, Y. Tao, et al. · Annals of Oncology · 97
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
2020 · Byoung Chul Cho, Amaury Daste, et al. · Journal for ImmunoTherapy of Cancer · 97
PDF
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)
2018 · Thomas Aparicio, Francois Ghiringhelli, et al. · Journal of Clinical Oncology · 96
PDF
Trends over three decades of the risk of second primary cancer among patients with head and neck cancer
2012 · Jérémie Jégu, Florence Binder-Foucard, et al. · Oral Oncology · 91
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial
2018 · Jaafar Bennouna, Sandrine Hiret, et al. · JAMA Oncology · 90
PDF
Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases
2001 · Bruno Cutuli, Christian Borel, et al. · Radiotherapy and Oncology · 90
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
2025 · Jean Bourhis, Anne Aupérin, et al. · The Lancet · 86
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2020 · Christian Borel, Alain C. Jung, et al. · Cancers · 81
PDF
Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma
2001 · T. Petit, C. Georges, et al. · Annals of Oncology · 81
PDF
Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial
2018 · Yungan Tao, Anne Auperin, et al. · Journal of Clinical Oncology · 78
Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.
2001 · T Petit, C Borel, et al. · PubMed · 77
Prognostic indicators for survival in head and neck squamous cell carcinomas: Analysis of a series of 621 cases
2005 · Christophe Le Tourneau, Michel Velten, et al. · Head & Neck · 72
NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
2025 · Jean Bourhis, Anne Auperin, et al. · Journal of Clinical Oncology · 71
Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.
1996 · R Mouawad, A Benhammouda, et al. · PubMed · 70
Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin ± taxane-pretreated ovarian cancer patients
2002 · V. Dieras, P. Bougnoux, et al. · Annals of Oncology · 65
PDF
NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.
2019 · Jerome Fayette, Caroline Even, et al. · Journal of Clinical Oncology · 62
Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France
2019 · A. Moya-Plana, A. Aupérin, et al. · European Journal of Cancer · 60
Works count: 145
Citation count: 4,223
H-index: 34
I10-index: 64
Year
Topic
Type